CRISPR THERAPEUTICS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.17 USD | -4.44% |
|
-8.45% | -18.26% |
Presenter SpeechSalveen Richter (Analysts)With that, Sam, thanks for joining us. And to start ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
51.17
USD
Average target price
86.78
USD
Spread / Average Target
+69.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.26% | 4.34B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 42nd Annual Global Healthcare Conference, Jun-08-2021 03
